Previous 10 | Next 10 |
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Sanjay S. Subramanian, M.S., MBA, as chi...
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief ...
H.C. Wainwright had initiated Inozyme Pharma (INZY +11.8%) with a buy based on optimism for its enzyme replacement therapy INZ-701. Wainwright has a $33 price target (~441% upside based on Friday's close). The candidate is in phase 1/2 for ENPP1 deficiency and in IND-enabling stages for ABCC6...
BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the first patient has been dosed in its first-in-human ...
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, p...
Inozyme Pharma (NASDAQ:INZY): Q3 GAAP EPS of -$0.60 beats by $0.01. Press Release Cash, cash equivalents, and investments were $125.3 million as of September 30, 2021. Based on its current plans and considering the impact of COVID-19-related clinical trial delays, the Company expect...
– On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety data in the first half of 2022 – – Cash, cash equivalents, and investments expected to support continue...
- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets - - Preclinical data support AAV-ENPP1 gene therapy as a potential treatment for ENPP1 Deficiency - ...
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-found...
Gainers: GreenSky (NASDAQ:GSKY) +53%. IronNet (NYSE:IRNT) +27%. Sphere (NASDAQ:ANY) +22%. Allied Healthcare Products (NASDAQ:AHPI) +19%. Actinium Pharmaceuticals ATNM +16%. Ampio Pharmaceuticals (NYSE:AMPE) +15%. Inozyme Pharma (NASDAQ:INZY) +15%. Seres Therapeutics (...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 20:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...